Submitted by Anonymous (not verified) on 29 November 2023 - 11:25
Human medicines European public assessment report (EPAR): Ruxience, rituximab, Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 01/04/2020, Revision: 11, Status: Authorised
Source: